Home

Biomarkers

The neurobiology of conversion to psychosis – emerging findings from the SHARP study

The clinical high risk (CHR) phase of schizophrenia when cognitive and social functioning begin to...

Congress highlights

Early effects of antidepressants – a clue to mechanism of action

The delay in onset of effect of antidepressant treatment can be frustrating both for the patient...

Congress highlights

Challenges and perspectives in the management of major depressive disorder: How can we bridge clinical predictors and biomarkers to better treatment outcomes for more patients?

Although the past 50 to 60 years of antidepressant drug development focusing on monoamines has...

Depression, Bipolar

Congress highlights

In search of biomarkers for mood disorders

Novel biomarkers for mood disorders will enable early diagnosis and inform the development of new...

Congress highlights

What is the role of inflammation in the pathophysiology of mood disorders?

Evidence supporting a role for inflammation and pro-inflammatory mediators in the pathophysiology...

Biomarkers - the Future of Diagnosis in Psychiatry?

Diagnosis of psychiatric disorders currently depends on clinical criteria. In the future the hope...

Refining and redefining diagnosis and prognosis in psychosis: can biomarkers and imaging help?

Consortia the world over are seeking biomarkers, including abnormalities on brain imaging, that...

Depression, Schizophrenia

Brain imaging: focus on predicting disease course and treatment response

Predicting disease course and predicting response to therapy – including the probability that...

Train, test, predict: Using big data and machine learning in psychiatry

Introduction of biomarkers for diagnosis and treatment of psychiatric diseases into routine...

Bipolar, Schizophrenia

Brain connectivity in early psychosis and during effective antipsychotic therapy

Resting state functional MRI of the brain is providing fascinating insights into the connectivity...

Congress highlights

Psychiatry’s white whale? The search for biomarkers for schizophrenia

Biomarkers are available and used effectively in other disorders– notably some of the cancers...

Schizophrenia – from prodrome to psychosis

Psychosis is preceded by a 3–4 year prodromal phase in 75% of patients, but only 25% of...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind South East Asia Continue to Progress in Mind South Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Finland Continue to Progress in Mind Japan Continue to Progress in Mind България Continue to Progress in Mind Israel Continue to Progress in Mind Ireland Continue to Progress in Mind Sweden Continue to Progress in Mind Finland Continue to Progress in Mind Ukraine

You are leaving Progress in Mind

Continue to

Cancel

You are leaving

Progress in Mind Portugal
HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in Portugal click here.

Continue to verification page Login with email

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

Accept

Decline